Physician profile
Drew Kuraitis
NPI 1184152449
$42,133.78
in general payments reported to CMS, 2019-2025
22 companies · $4,182 in 2025
The $4,182 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.72 · 2021: $2,621 · 2022: $15K · 2023: $18K · 2024: $2,217 · 2025: $4,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $5,952 · Travel and Lodging: $2,021 · Consulting Fee: $1,950 · Honoraria: $775 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,225.00 |
| Food and Beverage | $5,952.49 |
| Travel and Lodging | $2,020.53 |
| Consulting Fee | $1,950.00 |
| Honoraria | $775.00 |
| Education | $113.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32,867.09 | 2021-2025 | Targretin, Siliq, Arazlo |
| Ucb, INC. | $3,871.10 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $1,230.38 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Chiesi USA, INC. | $775.00 | 2024-2025 | Filsuvez |
| Novartis Pharmaceuticals Corporation | $587.09 | 2021-2025 | |
| Kyowa Kirin, INC. | $515.88 | 2023-2025 | Poteligeo |
| Bausch Health US, LLC | $470.52 | 2022-2023 | Targretin, Siliq |
| Regeneron Healthcare Solutions, INC. | $416.63 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $235.12 | 2022-2024 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $166.43 | 2022-2023 | Sotyktu |
| Abbvie INC. | $156.64 | 2021-2022 | |
| Pfizer INC. | $135.00 | 2024 | |
| Leo Pharma INC. | $121.79 | 2025 | Anzupgo |
| Janssen Biotech, INC. | $120.37 | 2021-2022 | |
| Genzyme Corporation | $115.45 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Incyte Corporation | $70.44 | 2021-2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.22 | 2022-2024 | Spevigo |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Krystal Biotech INC | $19.80 | 2025 | Vyjuvek |
| Genentech USA, INC. | $18.72 | 2020 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Kuraitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.